News & Updates
Filter by Specialty:
Rituximab shows promise in management of neuropsychiatric SLE
Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.
Rituximab shows promise in management of neuropsychiatric SLE
02 Jul 2024
Novel JAK1 inhibitor relieves symptoms in active RA
Use of the selective JAK1 inhibitor SHR0302 significantly improves the clinical signs and symptoms of patients with moderate-to-severe active rheumatoid arthritis (RA) who had shown poor response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to a study presented at EULAR 2024.
Novel JAK1 inhibitor relieves symptoms in active RA
02 Jul 2024
Organic pollutants found in Mediterranean diet up GDM risk
Adherence to a healthy dietary pattern, such as the Mediterranean diet (MedDiet), may reduce the risk of gestational diabetes mellitus (GDM) but appears to increase exposure to harmful chemicals, according to a Singapore study presented at ADA 2024.
Organic pollutants found in Mediterranean diet up GDM risk
01 Jul 2024
ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
A triplet regimen comprising the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) plus lenalidomide and rituximab (R2) inches its way into the R/R DLBCL* treatment path in the prespecified interim analysis of the ECHELON-3 trial, further reinforcing the role of BV in lymphoma treatment.
